{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:52:18Z","timestamp":1785174738238,"version":"3.55.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA036727"],"award-info":[{"award-number":["P30 CA036727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA258621"],"award-info":[{"award-number":["R01 CA258621"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Nebraska Medical Center Graduate Studies Assistantship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nitrogen bisphosphonates, such as zoledronic acid, target the enzyme farnesyl diphosphate synthase (FDPS) in the isoprenoid biosynthetic pathway (IBP), and are the frontline treatment for osteolytic bone diseases. A strong affinity of these agents for bone limits their distribution out of the skeleton. Geranylgeranyl diphosphate synthase (GGDPS) is directly downstream to FDPS in the IBP and novel GGDPS inhibitors such as RAM2061 have been shown to have key drug-like features including prolonged half-life, metabolic stability, and systemic distribution. Furthermore, RAM2061 exerts anti-neoplastic benefits in mouse models of multiple myeloma and Ewing sarcoma. Therefore, we are interested in determining the potential impact of RAM2061 on osteoclast biology and bone remodeling. Studies utilizing undifferentiated RAW264.7 cells demonstrated that treatment with RAM2061 depletes cells of geranylgeranyl diphosphate, impairs protein geranylgeranylation, and induces markers of the unfolded protein response pathway and apoptosis. Differentiation of RAW264.7 cells to mature osteoclasts is disrupted by RAM2061, resulting in decreased numbers of mature osteoclasts, altered morphology, and decreased tartrate-resistant acid phosphatase activity. Treatment of fully differentiated RAW264.7 cells with RAM2061 led to decreased resorptive activity. Confocal microscopy studies revealed that RAM2061 disrupts Cdc42 localization, inhibiting proper actin ring formation in osteoclasts. No significant impact on bone turnover markers or bone histomorphology was observed following a 3-week treatment of CD-1 mice with RAM2061, although decreased numbers of osteoclasts were observed. Liquid chromatography-tandem mass spectrometry studies confirmed accumulation of RAM2061 in bone from the in vivo studies as well as hydroxyapatite binding in vitro. In conclusion, these studies are the first to demonstrate the anti-osteoclastic activity of GGDPS inhibitor treatment and support future studies exploring the therapeutic benefit of this novel therapy in the setting of pathological bone remodeling.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziae133","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T19:08:02Z","timestamp":1729710482000},"source":"Crossref","is-referenced-by-count":3,"title":["Geranylgeranyl diphosphate synthase inhibition impairs osteoclast differentiation, morphology, and resorptive activity"],"prefix":"10.1093","volume":"9","author":[{"given":"Molly E","family":"Muehlebach","sequence":"first","affiliation":[{"name":"Cancer Research Doctoral Program, University of Nebraska Medical Center , Omaha, NE 68198,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci L","family":"Haney","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center , Omaha, NE 68198,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashpal S","family":"Chhonker","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Nebraska Medical Center , Omaha, NE 68198,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamunur","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Nebraska Medical Center , Omaha, NE 68198,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J","family":"Murry","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Nebraska Medical Center , Omaha, NE 68198,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Talmon","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, University of Nebraska Medical Center , Omaha, NE 68198,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9342-5635","authenticated-orcid":false,"given":"Sarah A","family":"Holstein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center , Omaha, NE 68198,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"37","key":"2024121808553871300_ref1","doi-asserted-by":"publisher","first-page":"25150","DOI":"10.1074\/jbc.M800882200","article-title":"Rho family GTPase modification and dependence on CAAX motif-signaled posttranslational modification","volume":"283","author":"Roberts","year":"2008","journal-title":"J Biol Chem"},{"issue":"5","key":"2024121808553871300_ref2","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1091\/mbc.e02-10-0639","article-title":"Membrane targeting of Rab GTPases is influenced by the prenylation motif","volume":"14","author":"Gomes","year":"2003","journal-title":"Mol Biol Cell"},{"issue":"1","key":"2024121808553871300_ref3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1021\/cb500791f","article-title":"Protein prenylation: enzymes, therapeutics, and biotechnology applications","volume":"10","author":"Palsuledesai","year":"2015","journal-title":"ACS Chem Biol"},{"key":"2024121808553871300_ref4","doi-asserted-by":"publisher","first-page":"e36620","DOI":"10.7554\/eLife.36620","article-title":"Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing bisphosphonates","volume":"7","author":"Yu","year":"2018","journal-title":"eLife"},{"issue":"1","key":"2024121808553871300_ref5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates","volume":"264","author":"van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2024121808553871300_ref6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","article-title":"Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298","volume":"15","author":"Coxon","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024121808553871300_ref7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/13543776.2019.1608180","article-title":"A patent review of bisphosphonates in treating bone disease","volume":"29","author":"Holstein","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"2024121808553871300_ref8","doi-asserted-by":"publisher","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","article-title":"Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton","volume":"139","author":"Rogers","year":"2020","journal-title":"Bone"},{"issue":"18","key":"2024121808553871300_ref9","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.2165\/0003495-200868180-00010","article-title":"Zoledronic acid: a review of its use in breast cancer","volume":"68","author":"Lyseng-Williamson","year":"2008","journal-title":"Drugs"},{"issue":"36","key":"2024121808553871300_ref10","doi-asserted-by":"publisher","first-page":"57932","DOI":"10.18632\/oncotarget.10773","article-title":"Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2024121808553871300_ref11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/jbmr\/zjad006","article-title":"Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study","volume":"39","author":"Brown","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024121808553871300_ref12","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2024121808553871300_ref13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro","volume":"96","author":"Fisher","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12 Suppl","key":"2024121808553871300_ref14","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+&lt;2961::aid-cncr12&gt;3.3.co;2-c","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"2024121808553871300_ref15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1124\/jpet.119.258624","article-title":"In vivo evaluation of isoprenoid triazole bisphosphonate inhibitors of geranylgeranyl diphosphate synthase: impact of olefin stereochemistry on toxicity and biodistribution","volume":"371","author":"Haney","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"26","key":"2024121808553871300_ref16","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1038\/s41388-019-0794-6","article-title":"Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma","volume":"38","author":"Haney","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"2024121808553871300_ref17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ddr.22012","article-title":"Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma","volume":"84","author":"Haney","year":"2023","journal-title":"Drug Dev Res"},{"issue":"9","key":"2024121808553871300_ref18","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.bmc.2014.03.014","article-title":"Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase","volume":"22","author":"Zhou","year":"2014","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"2024121808553871300_ref19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1021\/acsmedchemlett.5b00334","article-title":"Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase","volume":"6","author":"Wills","year":"2015","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"2024121808553871300_ref20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.bmc.2017.10.023","article-title":"\u03b1-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors","volume":"26","author":"Matthiesen","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"2024121808553871300_ref21","doi-asserted-by":"publisher","first-page":"105528","DOI":"10.1016\/j.phrs.2021.105528","article-title":"In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway","volume":"167","author":"Haney","year":"2021","journal-title":"Pharmacol Res"},{"issue":"1","key":"2024121808553871300_ref22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40164-022-00261-6","article-title":"Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma","volume":"11","author":"Haney","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"2024121808553871300_ref23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10637-018-0571-3","article-title":"Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor","volume":"36","author":"Haney","year":"2018","journal-title":"Investig New Drugs"},{"issue":"4","key":"2024121808553871300_ref24","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.leukres.2010.08.008","article-title":"Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells","volume":"35","author":"Holstein","year":"2011","journal-title":"Leuk Res"},{"key":"2024121808553871300_ref25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jpba.2018.02.010","article-title":"Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS\/MS: Derivatization and application","volume":"153","author":"Chhonker","year":"2018","journal-title":"J Pharm Biomed Anal"},{"issue":"12","key":"2024121808553871300_ref26","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23123275","article-title":"Simultaneous quantitation of isoprenoid pyrophosphates in plasma and cancer cells using LC-MS\/MS","volume":"23","author":"Chhonker","year":"2018","journal-title":"Molecules"},{"key":"2024121808553871300_ref27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejmech.2018.08.044","article-title":"Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis","volume":"158","author":"Savino","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"7","key":"2024121808553871300_ref28","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2024121808553871300_ref29","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1111\/jcmm.14277","article-title":"Overview of RAW264.7 for osteoclastogensis study: phenotype and stimuli","volume":"23","author":"Kong","year":"2019","journal-title":"J Cell Mol Med"},{"key":"2024121808553871300_ref30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-61779-415-5_13","article-title":"RANKL-mediated osteoclast formation from murine RAW 264.7 cells","volume":"816","author":"Collin-Osdoby","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2024121808553871300_ref31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/bf02411252","article-title":"Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function","volume":"34","author":"Minkin","year":"1982","journal-title":"Calcif Tissue Int"},{"issue":"22","key":"2024121808553871300_ref32","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1242\/jcs.086280","article-title":"Rac deletion in osteoclasts causes severe osteopetrosis","volume":"124","author":"Croke","year":"2011","journal-title":"J Cell Sci"},{"issue":"2","key":"2024121808553871300_ref33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1359\/jbmr.071013","article-title":"Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis","volume":"23","author":"Wang","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024121808553871300_ref34","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1172\/jci39650","article-title":"Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL\/M-CSF signaling and osteoclast polarization","volume":"120","author":"Ito","year":"2010","journal-title":"J Clin Invest"},{"issue":"1","key":"2024121808553871300_ref35","doi-asserted-by":"publisher","first-page":"e28119","DOI":"10.4161\/sgtp.28119","article-title":"Modulation of osteoclast differentiation and bone resorption by Rho GTPases","volume":"5","author":"Touaitahuata","year":"2014","journal-title":"Small GTPases"},{"issue":"3","key":"2024121808553871300_ref36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/s0006-291x(02)00326-1","article-title":"Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTP-binding Rab proteins","volume":"293","author":"Zhao","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"37","key":"2024121808553871300_ref37","doi-asserted-by":"publisher","first-page":"32356","DOI":"10.1074\/jbc.M414213200","article-title":"Possible role of direct Rac1-Rab7 interaction in ruffled border formation of osteoclasts","volume":"280","author":"Sun","year":"2005","journal-title":"J Biol Chem"},{"issue":"5","key":"2024121808553871300_ref38","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae034","article-title":"Molecular and functional mapping of Plekhm1-Rab7 interaction in osteoclasts","volume":"8","author":"Das","year":"2024","journal-title":"JBMR Plus"},{"issue":"12","key":"2024121808553871300_ref39","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1091\/mbc.e04-06-0522","article-title":"Apatite-mediated actin dynamics in resorbing osteoclasts","volume":"15","author":"Saltel","year":"2004","journal-title":"Mol Biol Cell"},{"issue":"10","key":"2024121808553871300_ref40","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1359\/jbmr.070701","article-title":"Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells","volume":"22","author":"Duque","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024121808553871300_ref41","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.bone.2009.01.009","article-title":"Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation","volume":"44","author":"Ebert","year":"2009","journal-title":"Bone"},{"issue":"6","key":"2024121808553871300_ref42","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/jcb.23087","article-title":"The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation","volume":"112","author":"Weivoda","year":"2011","journal-title":"J Cell Biochem"},{"issue":"2","key":"2024121808553871300_ref43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bone.2011.09.056","article-title":"Geranylgeranyl pyrophosphate stimulates PPAR\u03b3 expression and adipogenesis through the inhibition of osteoblast differentiation","volume":"50","author":"Weivoda","year":"2012","journal-title":"Bone"},{"issue":"22","key":"2024121808553871300_ref44","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1016\/j.febslet.2006.08.060","article-title":"Geranylgeranyl-pyrophosphate (GGPP) synthase is down-regulated during differentiation of osteoblastic cell line MC3T3-E1","volume":"580","author":"Yoshida","year":"2006","journal-title":"FEBS Lett"},{"issue":"1","key":"2024121808553871300_ref45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.bmc.2007.09.029","article-title":"Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors","volume":"16","author":"Wiemer","year":"2008","journal-title":"Bioorg Med Chem"},{"issue":"100","key":"2024121808553871300_ref46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bone.2014.06.023","article-title":"Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis","volume":"66","author":"Haider","year":"2014","journal-title":"Bone"},{"issue":"1","key":"2024121808553871300_ref47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","article-title":"The relationship between the chemistry and biological activity of the bisphosphonates","volume":"49","author":"Ebetino","year":"2011","journal-title":"Bone"},{"key":"2024121808553871300_ref48","doi-asserted-by":"publisher","first-page":"116289","DOI":"10.1016\/j.bone.2021.116289","article-title":"Bisphosphonates: the role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use","volume":"156","author":"Ebetino","year":"2022","journal-title":"Bone"},{"issue":"20","key":"2024121808553871300_ref49","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2024121808553871300_ref50","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"10","key":"2024121808553871300_ref51","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1093\/gerona\/glt046","article-title":"The relevance of mouse models for investigating age-related bone loss in humans","volume":"68","author":"Jilka","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"2024121808553871300_ref52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","article-title":"The anti-tumour effects of zoledronic acid","volume":"3","author":"Zekri","year":"2014","journal-title":"J Bone Oncol"},{"issue":"3","key":"2024121808553871300_ref53","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1021\/acsabm.0c01455","article-title":"Calcium-bisphosphonate nanoparticle platform as a prolonged nanodrug and bone-targeted delivery system for bone diseases and cancers","volume":"4","author":"Lin","year":"2021","journal-title":"ACS Appl Bio Mater"},{"issue":"7","key":"2024121808553871300_ref54","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.1021\/acsami.8b16588","article-title":"Zoledronic acid-containing nanoparticles with minimum premature release show enhanced activity against extraskeletal tumor","volume":"11","author":"Li","year":"2019","journal-title":"ACS Appl Mater Interfaces"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziae133\/60011167\/ziae133.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/1\/ziae133\/61218348\/ziae133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/1\/ziae133\/61218348\/ziae133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T08:56:02Z","timestamp":1734512162000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziae133\/7833426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziae133","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,10,23]]},"article-number":"ziae133"}}